1.	German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Phase: Phase IV Type: Treatment Status: Completed Age: 15 to 65 Sponsor: Other Protocol IDs: GMALL04, NCT00199017
2.	Phase III Randomized Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) vs Fludarabine (FAMP) for Pretreated B-Cell Chronic Lymphocytic Leukemia (Summary Last Modified 05/98) Phase: Phase III Type: Treatment Status: Closed Age: 18 to 79 Sponsor: Protocol IDs: EORTC-06942
3.	Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: SAKK 32/98, SWS-SAKK-32/98, EU-98074, NCT00003746
4.	Phase I/II Study of Cladribine Plus Interferon in Patients with Advanced Low Grade Lymphoid Malignancies (Summary Last Modified 03/2000) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NU-93H4, NCI-G99-1635
5.	phase I/II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) as a Pretransplant Immunosuppressive Agent to Prevent Graft Failure in Patients with Hematologic Malignancies Undergoing Transplant with T-Cell-Depleted Marrow from HLA-Haploidentical Donors (Summary Last Modified 05/98) Phase: Phase II, Phase I Type: Supportive care Status: Closed Age: 5 to 50 Sponsor: NCI Protocol IDs: FHCRC-126.8, NCI-T91-0013D, T91-0013
6.	Phase I/II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Adults with Acute Nonlymphoblastic Leukemia (Summary Last Modified 05/98) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 17 and over Sponsor: Protocol IDs: MSKCC-91094, NCI-V91-0185
7.	Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000619329, NCCTG-N078D, N078D, NCT00787969
8.	Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) Phase: Phase II, Phase I Type: Treatment Status: Temporarily closed Age: 18 and over Sponsor: Other Protocol IDs: PSHCI 10-011, NCT01439750
9.	Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Stage III/IV, Low- or Intermediate-Grade, Follicular non-Hodgkin's Lymphoma Previously Untreated with Chemotherapy (Summary Last Modified 05/98) Phase: Phase II Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Protocol IDs: SWS-SAKK-39/93, EU-93012
10.	Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) and Chlorambucil for B-Cell Chronic Lymphocytic Leukemia Previously Untreated with Chemotherapy (Summary Last Modified 05/98) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-938151, NCCTG-93-81-51
11.	Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Progressive or Recurrent Malignant Glioma (Summary Last Modified 05/98) Phase: Phase II Type: Treatment Status: Closed Age: over 18 Sponsor: Protocol IDs: UCCRC-7154, NCI-V94-0451
12.	Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Residual and Recurrent Primary CNS Malignancies (Summary Last Modified 05/98) Phase: Phase II Type: Treatment Status: Closed Age: over 18 Sponsor: Protocol IDs: MSKCC-94038, NCI-V94-0475
13.	Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Hairy Cell Leukemia Phase: Phase II Type: Treatment Status: Closed Age: any age Sponsor: Protocol IDs: SWS-SAKK-32/93, EU-94037
14.	Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) by 2-Hour Infusion for Previously Untreated B-Cell Chronic Lymphocytic Leukemia (Summary Last Modified 05/98) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: NU-LE94-52-005, NCI-V95-0666
15.	Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: under 22 Sponsor: NCI, Other Protocol IDs: CDR0000064907, CCG-2951, NCT00002805
16.	Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia Phase: Phase II Type: Treatment Status: Completed Age: 55 to 70 Sponsor: NCI, Other Protocol IDs: DM94-078, P30CA016672, MDA-DM-94078, NCI-G96-1001, CDR0000065035, NCT00002833
17.	Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Relapsed or Refractory Acute Myeloid Leukemia (Summary Last Modified 05/98) Phase: Phase II Type: Treatment Status: Closed Age: no age specified Sponsor: NCI Protocol IDs: E-5995, E5995
18.	Cladribine in Patients With Mantle Cell Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000065179, NCCTG-958053, NCT00002879
19.	Phase II Study of Sequential Cyclophosphamide/Prednisone and Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Previously Untreated B-Cell Chronic Lymphocytic Leukemia Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-958151, NCCTG-95-81-51
20.	Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia Phase: Phase II Type: Treatment Status: Completed Age: Under 21 at diagnosis Sponsor: NCI, Other Protocol IDs: CDR0000065993, COG-P9720, POG-9720, NCT00003178
21.	Phase II Study of Cladribine with Cyclophosphamide and Prednisone in Patients with B Cell Chronic Lymphocytic Leukemia or Low Grade Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18-75 Sponsor: Protocol IDs: SWS-SAKK-37/95, EU-97040
22.	Phase II Study of Low Dose Bolus Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Patients with Recurrent or Newly Diagnosed Hairy Cell Leukemia Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: SWS-SAKK-32/95, EU-97039
23.	Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Patients with Hematologic Malignancies Phase: Phase II Type: Treatment Status: Closed Age: 16 and over Sponsor: Protocol IDs: MDA-DM-88083, NCI-V89-0246
24.	Phase II Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Advanced Stage, Previously Untreated, Low-Grade Lymphomas Phase: Phase II Type: Treatment Status: Closed Age: over 18 Sponsor: NCI Protocol IDs: CLB-9153, CALGB-9153
25.	Phase II Trial of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) in Patients with B-Cell CLL Who Have Failed Fludarabine Phosphate Therapy Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CLB-9211, CALGB-9211